YOLFTbeta
69

TFBS Bioscience Inc.

6939 · TWO · Healthcare / Diagnostics & Research

18.65TWD+0.30 (+1.63%)

Price History

Full chart

Market Stats

Previous Close18.35
Open18.50
Day Range18.50 – 18.65
52-Week Range18.05 – 27.85
Volume1.01K
Market Cap689.99M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.88
Dividend Yield0.00%
50-Day Avg19.73
200-Day Avg20.32

About

TFBS Bioscience Inc., a contract research organization, provides biological testing services in Taiwan. It offers viral vector manufacturing services for cell and gene therapy products; and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products. The company was incorporated in 2016 and is headquartered in New Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. Tatung Yuan Ph.D.
  • HeadquartersNo.103, Ln. 169, New Taipei City, Taiwan, Taiwan
  • Websitehttps://www.tfbsbio.com

Leadership

  • Dr. Tatung Yuan Ph.D.Chairman & CEO
  • Mr. Wilson LiaoChief Financial Officer
  • Ms. Man Shiow JiangChief Technology Officer

Financials

Income Statement

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue118.57M160.88M252.72M231.92M180.56M193.14M
Growth (%)-+35.68%+57.08%-8.23%-22.15%+6.97%
Cost of Revenue84.00M106.83M148.67M168.60M143.04M156.32M
Gross Profit34.58M54.05M104.05M63.32M37.52M36.82M
Gross Margin29.16%33.59%41.17%27.30%20.78%19.06%
Operating Expense34.26M48.04M70.28M68.77M98.76M114.82M
Operating Income311.00K6.01M33.77M-5.45M-61.23M-78.00M
Operating Margin0.26%3.73%13.36%-2.35%-33.91%-40.39%
EBITDA25.91M32.76M68.33M64.15M2.24M-19.25M
EBITDA Margin21.85%20.36%27.04%27.66%1.24%-9.97%
Net Income296.00K6.12M27.69M4.91M-38.67M-74.52M
Net Income Margin0.25%3.81%10.96%2.12%-21.42%-38.58%
R&D21.02M25.97M33.66M36.25M45.74M64.80M
R&D as % of Total Revenue17.73%16.14%13.32%15.63%25.33%33.55%
Interest Expense357.00K306.00K647.00K602.00K841.00K2.81M
Interest Expense % of Total Revenue0.30%0.19%0.26%0.26%0.47%1.46%

Balance Sheet

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets288.36M491.30M1.36B1.45B1.50B1.46B
Total Liabilities40.41M66.44M126.18M187.44M265.14M294.72M
Total Equity247.95M424.86M1.24B1.26B1.23B1.16B
Cash76.13M240.91M976.44M929.35M515.92M307.32M
Total Debt19.67M21.35M52.19M131.77M196.16M-
Net Debt-56.46M-219.56M-924.25M-797.57M-319.76M-

Cash Flow

Currency: TWD2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow29.45M21.02M78.72M36.53M28.82M-9.74M
Investing Cash Flow-12.81M-19.36M-104.75M-57.63M-500.97M-
Financing Cash Flow-6.87M163.11M761.56M-25.99M60.46M-
Capital Expenditure13.34M19.04M49.83M55.88M372.78M225.42M
Free Cash Flow16.10M1.98M28.89M-19.36M-343.96M-235.16M
Dividends Paid---3.35M1.74M-
FCF to OCF54.68%9.42%36.70%-52.99%-1193.40%2414.13%
Dividend Paid to FCF----17.29%-0.51%-

Key Statistics & Ratios

Market Cap689.99M
Enterprise Value506.89M
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.52
Price / Book0.61
EPS-1.88
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding35.38M
Shares Float0
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20241×
0.05Aug 9, 2024
20231×
0.10Sep 27, 2023

Stock Splits

  • Sep 27, 20231040:1000